Oral Lipid-Based Formulations: Unlocking Value in Early-Stage Pharmaceutical Development

Become equipped to navigate preclinical and clinical stages of development for oral lipid-based formulations.

Register Free: https://www.pharmtech.com/pt_w/lipid-based-formulations

Event Overview:

Lipid-based formulations are more than just a tool for enhancing solubility and bioavailability - they are essential to navigating the complexities of preclinical and clinical development. Join our expert-led panel to explore innovative formulation strategies, the diverse mechanisms of action, preclinical and clinical considerations, as well as encapsulation techniques, and more.

Key Learning Objectives:

• Understand the multifaceted role of lipid-based formulations in early-stage drug development, extending beyond solubility and bioavailability.
• Navigate the preclinical to clinical considerations to optimize the development of lipid-based formulations.
• Explore innovative encapsulation techniques and their impact on drug stability and release profiles.

Who Should Attend:

• Chief scientific officers (CSOs)
• Chief medical officers (CMOs)
• Senior vice presidents (SVPs), VPs, and Directors
• Senior managers/managers
• Formulation scientists
• Biopharma industry consultants

Others with roles in:

• Research and development (R&D)
• Product development
• Chemistry, manufacturing, and control (CMC)
• Preclinical development
• Clinical development

Speakers:

René Holm
Professor of Pharmacy
University of Southern Denmark

René Holm, is a pharmaceutical expert who received his training and PhD from the University of Copenhagen in 1998 and 2002, respectively. He previously worked with Lundbeck. Since 2016, he has worked with Janssen. Dr Holm has worked in various fields, including physical chemistry, material science, and pharmaceutical development. He has co-authored more than 200 original articles and is currently a professor in pharmaceutical physical chemistry at the University of Southern Denmark.

Guillaume Enderlin
Senior Manager, Pharmaceutical Development
Catalent Beinheim

Guillaume Enderlin is senior manager of pharmaceutical development at the Catalent Beinheim site (France). He has worked for 12 years in softgel R&D, from formulation to manufacturing development process, building expertise to cover the whole Rx pharmaceutical development process. Guillaume is a pharmacist (PharmD) and has a Master’s degree in pharmaceutical engineering.

Christel Bergström
Professor, Molecular Pharmaceutics
Uppsala University Sweden

Christel Bergström is a professor of molecular pharmaceutics at Uppsala University, and is an adjunct professor at Monash University. She leads a research group on drug delivery for challenging compounds and has published over 100 articles. Bergström directs The Swedish Drug Delivery Center and plays key roles in the Nordic POP initiative. In 2019, she founded Enphasys AB, focusing on animal-free drug absorption models.

Ben J. Boyd
Professor, Drug Delivery Disposition & Dynamics
University of Copenhagen & Monash Institute of Pharmaceutical Sciences

Prof. Benjamin Boyd is a colloid and physical chemist with a PhD from the University of Melbourne. With industry experience in explosives and pharmaceuticals, he holds an academic position at Monash University and recently received a Novo Nordisk Laureate Research Fellowship at the University of Copenhagen. His research focuses on lipids, lipid self-assembly, and pharmaceutical systems, including synchrotron-based characterization. Prof. Boyd is also the President of the Controlled Release Society.

Lisa Caralli
Senior Director of Scientific Advisory
Catalent

Lisa Caralli is the senior director of scientific advisory at Catalent, overseeing small molecule and peptide scientific support for North America. She has over 30 years of industry experience in pharmaceutical research and development, with a focus on early-phase approaches to the chemistry manufacturing and control of small molecules and peptides. Lisa has held previous product development positions at Ionis Pharmaceuticals, Amylin Pharmaceuticals, and the Immune Response Corporation. She holds a BS in biochemistry from the University of California at Davis.

Register Free: https://www.pharmtech.com/pt_w/lipid-based-formulations